{'fraction_non_alphanumeric': 0.02316076294277929, 'fraction_numerical': 0.004087193460490463, 'mean_word_length': 4.6106870229007635, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
BENIGN PROSTATIC HYPERPLASIA: COUNTING THE COST OF ITS MANAGEMENT

BPH is estimated to affect around 3.2 million men of middle age and beyond in the UK. BPH not only has a serious effect on the quality of life of patients and their families; the condition is also expensive for the NHS, both in terms of costs both for GP practices in primary care, and for urology services in secondary care. Moreover, BPH, especially if acute urinary retention (AUR) develops, can have a very deleterious effect on an individual’s quality of life [1]. In the future the social and economic burden is only likely to increase with the rising numbers of men with bothersome LUTS resulting from the increasing prevalence of BPH in the ageing population.